Mirimus, Inc.
NY
- UEI
- CP76MKEFKFE4
- CAGE
- 6DUZ3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Jersey City, NJ M3E7XWR3SN95
-
- SAM.gov registration date
- Physical address
- 760 Parkside Ave #206, Brooklyn, NY 11226, USA
- Website
- mirimus.com
- Founded
- 2010
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$15,000 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $21,450 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Creative Enzymes | Shirley, NY | 541713 Research and Development in Nanotechnology |
| Genscript Probio USA Inc. | Pennington, NJ | 325414 Biological Product (except Diagnostic) Manufacturing |
| Codex Biosolutions Inc. | North Bethesda, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Discovery Life Sciences, LLC | Huntsville, AL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| BOC Sciences | Shirley, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Mirimus, Inc. is a corporate entity registered in SAM.gov since 2011, classified as a self-certified small disadvantaged business located in Brooklyn, NY. The company specializes in scientific research services, particularly in the areas of biological research, genetic engineering, and advanced therapeutic development. Mirimus demonstrates expertise in providing scientific supplies, reagents, testing services, and innovative research solutions to various federal agencies, with a strong focus on biomedical and medical research technologies.
Through federal contract awards, Mirimus has primarily worked with the National Institutes of Health (NIH), specifically the NIH Clinical Center and the National Heart, Lung and Blood Institute. The company has secured contracts for breeding and genotype services, scientific supplies, and specialized testing services. A notable contract was a $1.167 million firm fixed price award for saliva pool testing services in support of coronavirus monitoring efforts, specifically the RADX TECH II project for high-throughput detection and variant identification. These contracts have ranged in value from approximately $15,000 to $1.17 million, with contract types including purchase orders and definitive contracts, and all awards were made without specific set-aside designations.
Mirimus has received federal grant awards focused on advanced therapeutic research, particularly in RNA interference (RNAi) technologies and cancer research. The company was awarded a $700,000 grant from the National Institute of General Medical Sciences to develop next-generation RNAi therapeutics and create an in vivo model for evaluating their efficacy and biodistribution. Another significant grant of unspecified amount was received from the National Cancer Institute to support preclinical evaluation of a novel ADAM10 modulator for treating colorectal cancer. These grants aim to accelerate the development of innovative biological drug candidates, with a focus on creating sophisticated research models and exploring targeted therapeutic approaches for complex medical conditions.
Quick answers
Is Mirimus, Inc. registered in SAM.gov?
Yes. Mirimus, Inc.'s SAM.gov registration is active through January 13, 2027.
How much has Mirimus, Inc. received in federal contracts?
Federal contracts obligated $6,450 to Mirimus, Inc. in fiscal years 2023 through 2027.
What is Mirimus, Inc.'s most recent federal award?
Mirimus, Inc.'s most recent federal grant award is Creation of the next generation rnai therapeutics and an in vivo model for their study (R43GM154496), from National Institute of General Medical Sciences (NIH), on September 20, 2024.
On GovTribe
See Mirimus, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors